A federal appeals court has restricted access to one of the most common methods of abortion in the United States by blocking the mailing of mifepristone prescriptions. The ruling requires that the medication be distributed only in person at clinics, effectively overruling regulations established by the federal Food and Drug Administration.
A Unanimous Judicial Shift
The decision came Friday from a three-judge panel of the Recent Orleans-based 5th U.S. Circuit Court of Appeals. In a unanimous ruling, the panel agreed with the state of Louisiana that allowing the drug to be mailed makes the state’s ban on abortion at all stages of pregnancy moot.
Judge Kyle Duncan, who was appointed by President Donald Trump, stated that every abortion facilitated by the FDA’s action cancels Louisiana’s ban on medical abortions. The ruling notes that this undermines the state policy that every unborn child is a human being from the moment of conception and is a legal person.
Impact on National Abortion Access
This ruling is described as the biggest jolt to U.S. Abortion policy since the 2022 Supreme Court decision that overturned Roe v. Wade. As the majority of abortions in the U.S. Are provided via pills, the restriction on mailing has wide-reaching implications.
Surveys indicate that about 1 in 4 abortions nationally are prescribed via telehealth. Last year, one survey of abortion providers estimated that more women in states with abortion bans obtained abortions through this method than by traveling to other states.
Conflict Over FDA Regulations
The court’s decision diverges from the usual practice of deferring to the FDA’s scientific judgments. The judges, all nominated by Republican presidents, noted that the FDA admitted it was still collecting data and could not say when a new review of the drug’s safety—directed by President Trump—might be complete.
During the COVID-19 years, the FDA dropped requirements for in-person appointments and certified physicians, stating that 20 years of monitoring and dozens of studies involving thousands of women showed the pill could be used safely without direct supervision.
GenBioPro, a manufacturer of generic mifepristone, stated that the court’s decision ignores rigorous science and decades of safe use. Meanwhile, the National Right to Life Committee’s president, Carol Tobias, said the ruling restores a critical layer of oversight and argues that women deserve better than a system that prioritizes ideology over safety.
Nationwide Consequences
The ruling is in effect as the case moves through the courts and extends beyond Louisiana and states with existing bans. Telehealth prescriptions, which have become common even in states where abortion is legal, are now blocked.
Julia Kaye, a lawyer with the ACLU, stated that this will affect access to abortion and miscarriage care in every state. Kaye noted that rural communities, people with low incomes, people with disabilities, survivors of intimate partner violence, and communities of color suffer the most when telemedicine is restricted.
Marjorie Dannenfelser, president of Susan B. Anthony Pro-Life America, called the ruling a huge victory against a reckless mail-order drug regime. She criticized the Trump administration’s slow movement in conducting its own review, arguing that such delays forced states to grab action.
Potential Legal Next Steps
The case is likely to be appealed to the U.S. Supreme Court. Danco Laboratories, a manufacturer and defendant in the suit, has asked the appeals court to put the order on hold for one week to seek relief from the high court.
If the request for a hold is not granted, the company said it will file an emergency appeal. While the Supreme Court preserved access to mifepristone in 2024, that decision did not address the core issues, as it ruled the anti-abortion doctors in that specific case lacked legal standing to sue.
Louisiana Attorney General Liz Murrill, a Republican, stated she looks forward to continuing to defend women and babies as the case continues.
Frequently Asked Questions
What is mifepristone and how is it used?
Mifepristone was approved in 2000 to safely and effectively end early pregnancies. It is usually used in combination with another drug called misoprostol.
How does the appeals court ruling change the distribution of the drug?
The ruling blocks the mailing of mifepristone prescriptions and requires that the drug be distributed only in person at clinics, overruling previous FDA regulations.
Does this ruling only affect states where abortion is banned?
No. The ruling is in effect nationwide and blocks telehealth prescriptions even in states where abortion is legal.
How do you think the restriction of telehealth services will impact healthcare access in rural communities?